Omnicare — Q4 2013 Earnings Presentation
18 slides from Omnicare's earnings presentation, Feb 19, 2014
Slide 1: Omnicare
Omnicare
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti
Slide 3: Table of Contents
Table of Contents Fourth-Quarter 2013 Highlights _ Fourth-Quarter 2013 Segment Highlights. . _ Operating Metrics — Script Data........... Gross Profit & Adjusted Operating Income... Adjusted Net Income & Cash EPS. . Adjusted Operating Income by Segment . . Cash Flows Cash Deployment... 2014 Guidance
Slide 4: Fourth-Quarter 2013 Highlights
Fourth-Quarter 2013 Highlights Adjusted Diluted Cash EPS) | aazo1s | Full-Year 2013 * Adj. Cash EPS - from Continuing Operations $0.87 $3.43 + Adj. Cash EPS - from Discontinued Operations?) $0.03 $0.18 + Adj. Cash EPS - Total $0.90 $3.61 | ° Revenue of $1,536M; 5.1% year-over-year increase * Gross p
Slide 5: Fourth-Quarter 2013 Segment Highlights
Fourth-Quarter 2013 Segment Highlights + Long-Term Care Group: — Q4 represents third consecutive quarter of net organic bed growth + Achieved full-year 2013 net organic bed growth — Adjusted operating income" of $160.4M; 3.5% higher than 4Q12 — Adjusted operating margin") of 13.72%; increased 47 bps
Slide 6: Operating Metrics
Operating Metrics Script Data Sequential Prior Year Increase / Increase / (In thousands, except %s) 4Q 2013 3Q2013 (Decrease) _4Q2012 (Decrease) Long-Term Care Group Scripts: Generic scripts aepensed 20,404 20,469 (0.3%) 20,970 (2.7%) Branded scripts disp 4,215 4,194 0.5% 4,023 4.8% Over-the- sounte
Slide 7: Gross Profit & Adjusted Operating Income
Gross Profit & Adjusted Operating Income )2) Sequential Prior Year rease / Increase / In millions, except per share data and %s _4Q2013_ _3Q2013 (Decrease) _4Q2012 (Decrease) Net sales $1,536.2 $1,515.2 1.4% $ 1,462.2 5.1% Cost of sales 1,176.5 1,163.2 1.1% 1,106.7 6.3% Gross profit $ 359.7 $ 352.0
Slide 8: Adjusted Net Income & Cash EPS
Adjusted Net Income & Cash EPS) k Sequential Prior Year i Increase / In millions, except per share data and %s 4a asia 30.2013 2013 pea 4a 2012 (Decrease) i $ 1443 $ 144.3 126.3 14.9% [ Interest expense, net of investment income 3. 3 (2 3 3 0) (23.7) 04% cused income before income taxes 120.6 © 120.
Slide 9: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment “) Increase/ YTD Increase / 40.2013 _4Q.2012 (Decrease) 12/31/13 _12/31/12__(Decrease) In millions, except %s Care Group Net sales $ 1,169.1 $ 1,169.7 (0%) $ 4,627.9 $ 4,789.6 (8%) Adjusted operating income® 160.4 155.0 3% 34.1 614.1 3% Rate 13.72% 13.25% 47 bps
Slide 10: Cash Flows
Cash Flows “) i Sequential Prior Year se / Increase / In millions, except %s 40.2013 302013 Desa 4Q 2012 (Decrease) Net income / (Loss) “S @37) $ (663) 59.0 (241 | (income) / Loss from discontinued operations $ 1423 $ (3.1) we: 2) $ (6.8) (253.4%) Adjustments to reconcile net income to net cash flow
Slide 11: Cash Deployment
Cash Deployment Increase / YTD YTD _ Increase / In millions, except %s 40.2013 42012 (Decrease) 12/31/13 12/31/12 (Decrease) Net cash flows from operating activities of continuing operations (reported) $ 235 $1195 (80.3%) $4795 $534.6 (10.3%) Capital expenditures 24.7 27.6 (21.4%) 95.0 96.9 (2.0%) A
Slide 12: Full-Year 2014 Guidance
Full-Year 2014 Guidance FY2014 5 f ne pee Net sales $6.0B $6.3B to $6.4B 5.0% to 6.7% Adjusted cash earnings per diluted share from $3.43 $3.64 to $3.72 6.1% to 8.5% continuing operations) Casinitouicerm emtioulig $480M® $475M to $550M 1.0% to 14.6% operations®)@) + Anticipate double-digit revenue,
Slide 13: Forward-Looking Major Financial Drivers
Forward-Looking Major Financial Drivers * Volume Growth — Long-Term Care Neutral Positive Positive ° Nellata erent = Sistetelhiy Ga Positive Positive Positive + Brand-to-generic Neutral Neutral Positive + Brand Drug Inflation Positive Positive Positive * Payer Pricing Negative Negative Negative + St
Slide 14: Appendix
RNY ly, “yg; Omnicare Appendix
Slide 15: Capital Structure
Capital Structure Major Debt Maturity Schedule) (in $ millions) s100 $1,500 $1,200 $900 $600 $300 \ | | a 2010 2015 2020 a 2030 2035 2040 2045, [ Recent actions have reduced refi risk by sp jing out ities while also ing costs stor 093, 2019 seo 2 omnicare m8
Slide 16: Working Capital Management
Working Capital Management Five Quarter Trend() 45 75 40 70 B35 65 5 6 30 60 = > g £25 55 6 3 20 50 8 3 rs o08 49.6 z § 15 45 445 10 29 a7 40 5 35 4are 1013 2013 3013 4013 “=e=Days of Inventory On Hand (DOH) © =®=Days Sales Outstanding (DSO) The timing of ives resulted in an elevated inventory balan
Slide 17: Selected Branded Drug Patent Expirations
Selected Branded Drug Patent Expirations) 2014 2014 2015 Rapamune (sua) 2, Drugs ahead aunched shown nay and ities 1014 Avelox (Tabs) Collcept (ora! susp) Nexium (caps) Rapamune (imo, 2v3) sana Invega ER 4Q14 Exforge IRVHCT Intuniv Oxycontin 2016 Kaletra (Tabs) Seroquel XR Zetia 2 omnicare
Slide 18: Omnicare
Omnicare